Featured Research

from universities, journals, and other organizations

Biodegradable Implant Holds Promise As Ovarian Cancer Treatment

Date:
February 6, 2007
Source:
University of Toronto
Summary:
A collaborative effort between researchers at the Leslie Dan Faculty of Pharmacy has resulted in an advanced drug delivery system for the treatment of ovarian cancer. PoLi, developed by Professors Micheline Piquette-Miller and Christine Allen, is a surgical implant that effectively kills cancer cells while minimizing the side effects of chemotherapy.

From left, Professor Christine Allen of pharmacy, PhD candidate Justin Grant and Professor Michelle Piquette-Miller of pharmacy have developed a promising new drug delivery system.
Credit: Image : Mike Andrechuk

A collaborative effort between researchers at the Leslie Dan Faculty of Pharmacy has resulted in an advanced drug delivery system for the treatment of ovarian cancer. PoLi, developed by Professors Micheline Piquette-Miller and Christine Allen, is a surgical implant that effectively kills cancer cells while minimizing the side effects of chemotherapy.

Ovarian cancer patients normally undergo two procedures: surgery to remove the tumour and chemotherapy to destroy any remaining cancer cells. The chemical vehicle used to intravenously transport anti-cancer drugs such as paclitaxel during chemotherapy can often cause serious side effects, including hypersensitivity and nervous system disorders.

The PoLi implant is a small hydrogel infused with cancer-killing drugs. It is applied directly to the ovary after the removal of the tumour and steadily releases the drug over a two-month period. The implant is biodegradable and dissolves naturally — it does not have to be surgically removed.

“The PoLi implant is showing promise in the treatment of other cancers, including head and neck,” Piquette-Miller said. “We are also developing an injectable gel-based formulation that could be administered directly to the tumour site without surgery. We would consider it for breast and prostate cancers.”

PoLi is the result of four years of collaboration between researchers who come from different scientific backgrounds. Allen, a materials science chemist, designed the implant, while Piquette-Miller, a molecular pharmacologist, determined the drug concentrations and PoLi’s potential applications. “Our team works well because there’s a real complement of expertise,” Allen said. “We also have a large number of students who are getting incredible interdisciplinary exposure.”

Justin Grant, a PhD candidate in Allen’s lab, has been with the project since Day 1. “Under Dr. Allen’s guidance I was able to design the PoLi drug delivery system, which became the focus of my PhD project,” Grant said. “As this system developed, we sought collaboration with Dr. Piquette-Miller’s lab for their expertise in pharmacokinetics and drug transporters. This implant system that started at a lab bench now has the potential to improve the quality of life for thousands of people.”

To move PoLi one step closer to treating humans requires clinical trials. A possible partnership with industry is being explored through Innovations at U of T. “The data showing the drug release profile, the lack of toxicity and the biocompatibility of the PoLi technology tell us that this technology has limitless potential,” said Jennifer Fraser, director of commercialization-life sciences at Innovations at U of T. “It would be a valuable asset to any company working in the drug delivery or cancer treatment space.”

Companies looking to develop PoLi for healthcare uses unrelated to cancer have also shown interest in the patented technology. “We’ve been approached by companies looking to develop it for wound healing and ocular diseases,” said Allen.

On advancing PoLi as a cancer treatment, the duo say they are keeping their options open. “Either we get the funding to advance the studies on our own or we work with industry,” Piquette-Miller said. “But our goal is to have both the implant and injectable formulations developed and see them go forward in the treatment of cancers.”


Story Source:

The above story is based on materials provided by University of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University of Toronto. "Biodegradable Implant Holds Promise As Ovarian Cancer Treatment." ScienceDaily. ScienceDaily, 6 February 2007. <www.sciencedaily.com/releases/2007/02/070204132832.htm>.
University of Toronto. (2007, February 6). Biodegradable Implant Holds Promise As Ovarian Cancer Treatment. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2007/02/070204132832.htm
University of Toronto. "Biodegradable Implant Holds Promise As Ovarian Cancer Treatment." ScienceDaily. www.sciencedaily.com/releases/2007/02/070204132832.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins